Walgreens Swings To Quarterly Loss As Lower Sales, Opioid Settlement Take A Toll

  • Walgreens Boots Alliance Inc's WBA Q1 FY23 sales decreased 1.5% Y/Y to $33.4 billion, up 1.1% on a constant currency basis, beating the consensus of $32.83 billion.
  • Adjusted EPS reached $1.16, down 29.9% on a constant currency basis, reflecting higher COVID-19 vaccine volumes, beating the consensus of $1.13.
  • The company swung to an operating loss of $6.2 billion compared to an operating income of $1.3 billion a year ago. Operating loss in the quarter reflects a $6.5 billion pre-tax charge for opioid-related claims and litigation.
  • The company said it administered 8.4 million COVID-19 vaccinations in the quarter, down from around 15.6 million a year earlier but up from 2.9 million doses administered in the prior quarter.
  • Guidance: Walgreens also raised its FY23 sales guidance to $133.5-$137.5 billion, citing the purchase of Summit Health and currency fluctuations, vs. the consensus of $134.80 billion.
  • Walgreens maintains FY23 adjusted EPS of $4.45-$4.65 (consensus of $4.48) as strong core business growth is more than offset by lapping FY22 COVID-19 execution and currency headwinds.
  • Price Action: WBA shares are down 4.24% at $35.91 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsGuidanceHealth CarePre-Market OutlookMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!